NeuBase is accelerating the genetic revolution with a new class of broad-based but highly targeted medicines
Based in Pittsburgh, Pennsylvania, NeuBase Therapeutics, Inc. (NBSE) is among the brightest hidden gems in the field of modern precision genetic medicines.
NeuBase’s product candidates are specifically designed to increase, decrease, or change gene function in order to resolve the genetic defects that drive disease.
With an initial focus on silencing disease-causing mutations in debilitating neuromuscular, neurological and oncologic disorders, NeuBase Therapeutics is committed to redefining medicine for the millions of patients with both common and rare conditions
Truly, this is leading-edge science in the rapidly growing genetics medicine field. At the same time, NBSE stock is highly affordable and well-positioned for a quick move in the near future.
A Closer Look at NBSE Stock
Market technicians like to watch the 52-week range as a gauge of whether a stock is currently cheap or expensive on a relative basis.
Let’s see how we can apply this metric to NBSE stock now. As of mid-December, NBSE’s 52-week range was between $2.58 and $12.89.
That’s a wide range, but low-priced stocks are sometimes known to be fast movers. This can be a good thing if you happen to pick up shares near the bottom of a stock’s defined price range.
In the case of NBSE stock, it was recently trading very close to $2.58, so it was definitely closer to the historical bottom than the top.
The ideal strategy in this situation, then, would be to “play the range” and start a position in the $2’s and $3’s, in anticipation of another share-price move towards $13.
Drugging the Genome
NeuBase Therapeutics’ approach to the advancement of genomic science is quite unique. Through the company’s proprietary genome-targeting platform, NeuBase seeks to target genes to increase or decrease proteins, or edit protein function with selectivity and tolerability.
As the company succinctly puts it, NeuBase Therapeutics is Drugging the Genome to address disease at the base level using a new class of precision genetic medicines.
Importantly, NeuBase’s compounds are designed to target the underlying causes of rare and common diseases, including cancers.
This suggests broad-based therapeutic potential, addressing up to around 7,000 rare diseases affecting roughly 10% of the global population. The need for solutions is imminent, as an estimated 1.9 million new cancer cases were diagnosed and around 600,000 cancer deaths occurred in the U.S. alone in 2021.
Thus, NeuBase Therapeutics is developing its modular peptide-nucleic acid antisense oligonucleotide (PATrOL) platform to address genetic diseases caused by mutant proteins with a single, cohesive approach.
Moreover, the company has three high-potential, pre-clinical programs in its pipeline: Myotonic Dystrophy (DM1), Huntington’s Disease (HD), and Oncology.
Positive Data in Hand
Checking in on NeuBase’s latest update on these pre-clinical programs, we’re glad to find that NeuBase Therapeutics Founder, CEO, and Chairman Dietrich A. Stephan has great news to share.
Earlier this year, NeuBase Therapeutics presented preclinical in vivo data of novel compounds demonstrating selective silencing of disease-causing mutations at the DNA or RNA level in three diseases, each of which is caused by a different underlying genetic mechanism.
“These new data further illustrate the broad applicability of our genetic medicine platform,” Stephan explained.
Furthermore, it was found that, following intravenous or subcutaneous dosing, these novel compounds were well tolerated at pharmacologically active doses. In addition, the compounds achieved targeted delivery into brain and muscle – and these results further support NeuBase’s claim of offering the unique ability to deliver genetic medicines throughout the body.
Concerning NeuBase’s lead program in DM1, recent data support a differentiated therapeutic approach to maintain DMPK function while selectively silencing the disease-driving mutation.
“With these positive data in hand, we believe we have a clear path towards entering the clinic and are planning for an IND filing in the fourth quarter of calendar year 2022,” Stephan concluded.
Looking toward the future, NeuBase Therapeutics is continuing to advance its therapeutic program for Huntington’s disease. With this, Stephan assures that NeuBase’s proprietary delivery technology “will allow our compounds to advance beyond intrathecal delivery, overcoming challenges seen with other programs.”
The Bottom Line
The positive data only serves to re-affirm NeuBase Therapeutics’ unique position in the field of precision genetic medicine.
As more data is released in the future, we should expect further progress as NeuBase effectively “Drugs the Genome.”
And if you haven’t taken a close look at NBSE stock yet, this is a perfect time to do so. The price is right, and you won’t go wrong with a stake in a data-driven, genome-targeted innovator like NeuBase Therapeutics.
